Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monoclonal antibodies for the treatment of Ebola virus disease.

Expert opinion on investigational drugs - 1 Nov 2016

Moekotte A L, Huson M A M, van der Ende A J, Agnandji S T, Huizenga E, Goorhuis A, Grobusch M P

Abstract excerpt

INTRODUCTION: To date, the management of patients with suspected or confirmed Ebolavirus disease (EVD) depends on quarantine, symptomatic management and supportive care, as there are no approved vaccines or treatments available for human use. However, accelerated by the recent large outbreak in West Africa, significant progress has been made towards vaccine development but also towards specific treatment with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Disease Outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Epitopes

Share to Hemorrhagic Fever, Ebola

Share to Mutation

Source

Identifiers

PMID: 27676206
DOI: 10.1080/13543784.2016.1240785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monoclonal antibodies for the treatment of Ebola virus disease.PMID 27676206Read ↗

Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.Semantic proximity Read ↗

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus ImmunotherapeuticSemantic proximity Read ↗

Early insights into viability of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreakSemantic proximity Read ↗

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protectionSemantic proximity Read ↗

Expanding the watch list for potential Ebola virus antibody escape mutationsSemantic proximity Read ↗

Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membraneSemantic proximity Read ↗

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse ModelSemantic proximity Read ↗

AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challengeSemantic proximity Read ↗

Sub-neutralizing concentrations of Zika virus IgM monoclonal antibodies reduce IgG-mediated antibody-dependent enhancement of infectivitySemantic proximity Read ↗

Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining.Semantic proximity Read ↗

Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.Semantic proximity Read ↗

A broadly-neutralizing antibody against <i>Ebolavirus</i> glycoprotein that potentiates the breadth and neutralization potency of other antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.